Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Taurine supplement tested as cheap fix for long COVID dizziness

NCT ID NCT07312409

Symptom relief Sponsor: York University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking taurine—a natural amino acid—for 12 weeks can improve blood vessel function and reduce dizziness when standing up in people with Long COVID. Researchers will measure blood flow, heart rate, and brain blood flow in 30 participants before and after supplementation. If successful, taurine could offer an affordable way to ease some Long COVID symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
taurine (a dietary supplement)
What this could lead to
If it works, this could point toward a simple, low-cost supplement to ease blood flow and dizziness problems in Long COVID.
What could go wrong
This is a very small early study (30 people) with no placebo group, so results may not be reliable or apply to everyone. Taurine is generally safe but may not help all symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Men and women aged 18-65 will be recruited who have been diagnosed by a medical professional with Long COVID, which is defined as persistent symptoms for \>3 months after a COVID infection. Participants will also need to experience orthostatic intolerance, which is the feeling of dizziness or faintness when standing for a prolonged period. Participants must be able to transport themselves to York University and undergo testing which will take approximately 90 minutes. This includes the ability to undergo a tilt table test for 5 minutes. Therefore, any musculoskeletal problems which prevent upright posture will be excluded. Participants must be able to communicate in English and have the ability to be contacted by email or phone throughout the 12-week period. Current smokers will be excluded. Participants who regularly consume energy drinks that contain taurine (more than once per week) will be excluded.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants will have had symptoms of Long COVID post-infection for at least 3 months Exclusion Criteria: * Inability to undergo tilt table testing for 5 minutes * Inability to transport selves to York University from their homes * Inability to speak English, or provide a translator * Blood clotting disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • York University

    RECRUITING

    Toronto, Ontario, M3J1P3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.